Page 72 - Read Online

Tarantino et al. Cancer Drug Resist 2019;2:43-52 I http://dx.doi.org/10.20517/cdr.2018.22 Page 51
REFERENCES
1. Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ 1997;314:1843-4.
2. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, et al. Rationale for biomarkers and surrogate end points in mechanism-driven
oncology drug development. Clin Cancer Res 2004;10:3885-96.
3. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, et al. UGT1A1 gene variations and irinotecan treatment in patients with
metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
4. US FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/
ucm572698.htm. [Last accessed on 27 Feb 2019]
5. Pharmacogenetics FDA. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from: http://www.fda.gov/Drugs/
ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. [Last accessed on 27 Feb 2019]
6. Thomas F, Thomas C. The anticancer drug development pipeline of the pharmaceutical (P) and biotech (B) industries. J Clin Oncol
2009;27.
7. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet
2013;14:23-34.
8. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ
2016;47:20-33.
9. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, et al. Failure of investigational drugs in late-stage clinical
development and publication of trial results. JAMA Intern Med 2016;176:1826-33.
10. Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program. Available from:
https://endpts.com/hammered-by-a-series-of-setbacks-newlink-axes-staff-again-and-circles-its-wagons-around-ido/. [Last accessed on
27 Feb 2019]
11. FDA. 22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results. US Food Drug Adm; 2017. pp. 1-43.
12. Cook D, Brown D, Alexander R, March R, Morgan P, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-
dimensional framework. Nat Rev Drug Discov 2014;13:419-31.
13. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, et al. Impact of a five-dimensional framework on R&D productivity at
AstraZeneca. Nat Rev Drug Discov 2018;17:167-81.
14. Motulsky AG. Drug reactions, enzymes, and biochemical genetics. J Am Med Assoc 1957;165:835.
15. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency:
genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
16. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, et al. Clinical pharmacogenetics implementation consortium
guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91.
17. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk
of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
18. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine
dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996;98:610-5.
19. Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, et al. DPYD genotype-guided dose individualisation of
fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:1459-67.
20. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, et al. UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and
capecitabine. Invest New Drugs 2013;31:1559-67.
21. Dean L. Irinotecan therapy and UGT1A1 genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors.
SourceMedical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
22. Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, et al. Prevalence of a common point mutation in the
dihydropyrimidine dehydrogenase (DPD) gene within the 5’-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-
related toxicity compared with controls. Clin cancer Res 2001;7:2832-9.
23. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, et al. Delivering precision medicine in oncology today and in future-the
promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann
Oncol 2014;25:1673-8.
24. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017;377:62-70.
25. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, et al. Molecularly targeted therapy based on tumour molecular profiling
versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2
trial. Lancet Oncol 2015;16:1324-34.
26. Krop IE. Results from molecular analysis for therapy choice (MATCH) arm I: taselisib for PIK3CA-mutated tumors. J Clin Oncol
2018;36:101.
27. Jhaveri KL. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/
gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy
Choice (MAT). J Clin Oncol 2018;36:100.
28. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and
children. N Engl J Med 2018;378:731-9.
29. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
30. O’Donnell PH, Stadler WM. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer
Res 2012;18:2809-16.